Evidence map›Paper›PMID 24417705›Full record

ReviewTissue engineering. Part B, Reviews2014

Tissue engineering approaches to cell-based type 1 diabetes therapy.

Luke D Amer, Melissa J Mahoney, Stephanie J Bryant

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Tissue engineering. Part B, Reviews, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.

0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

15 citing papers in PubMed.

  1. Review
  2. Article
  3. Review
  4. Article
  5. Review
  6. Nanofiber-based systems intended for diabetes.Journal of nanobiotechnology · 2021
    Review
  7. Review
  8. Review
  9. Review
  10. Review
  11. Article
  12. Review
  13. Article
  14. Article
  15. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Luke D Amer1 Department of Chemical and Biological Engineering, University of Colorado , Boulder, Colorado.
Melissa J Mahoney
Stephanie J Bryant

Funding

Generation of functional beta cells from stem and progenitor cellsU01DK089561 · NIDDK · UNIVERSITY HEALTH NETWORK · PI KELLER, GORDON, STREETER, PHILIP R · 2010 to 2014
$3.9M
NIDDK NIH HHS DK089561
6 · The paper itself

Abstract

Type 1 diabetes mellitus is an autoimmune disease resulting from the destruction of insulin-producing pancreatic β-cells. Cell-based therapies, involving the transplantation of functional β-cells into diabetic patients, have been explored as a potential long-term treatment for this condition; however, success is limited. A tissue engineering approach of culturing insulin-producing cells with extracellular matrix (ECM) molecules in three-dimensional (3D) constructs has the potential to enhance the efficacy of cell-based therapies for diabetes. When cultured in 3D environments, insulin-producing cells are often more viable and secrete more insulin than those in two dimensions. The addition of ECM molecules to the culture environments, depending on the specific type of molecule, can further enhance the viability and insulin secretion. This review addresses the different cell sources that can be utilized as β-cell replacements, the essential ECM molecules for the survival of these cells, and the 3D culture techniques that have been used to benefit cell function.

Indexed as

Biocompatible MaterialsCell Culture TechniquesDiabetes Mellitus, Type 1Extracellular MatrixHumansInsulin-Secreting CellsTissue EngineeringBiocompatible Materials

Identifiers

PMID24417705
PMCPMC4185974

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.